ResMed
871 hedge funds and large institutions have $20.7B invested in ResMed in 2024 Q4 according to their latest regulatory filings, with 151 funds opening new positions, 333 increasing their positions, 265 reducing their positions, and 68 closing their positions.
122% more first-time investments, than exits
New positions opened: 151 | Existing positions closed: 68
26% more repeat investments, than reductions
Existing positions increased: 333 | Existing positions reduced: 265
9% more funds holding
Funds holding: 801 → 871 (+70)
2.27% more ownership
Funds ownership: 59.43% → 61.7% (+2.3%)
3% less capital invested
Capital invested by funds: $21.3B → $20.7B (-$587M)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
79% less call options, than puts
Call options by funds: $86.1M | Put options by funds: $416M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$168M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$136M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$110M |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$95.1M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$86.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Greenvale Capital
London,
United Kingdom
|
-$171M |
| 2 |
Morgan Stanley
New York
|
-$145M |
| 3 |
Coatue Management
New York
|
-$116M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$95.3M |
| 5 |
Millennium Management
New York
|
-$87.7M |
RMD Hedge Fund Activity: Q4 2024 in Review
871 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q4 2024, worth a combined $20.7B — down 2.8% from $21.3B a quarter earlier.
Buyers outnumbered sellers: 151 funds opened new RMD positions and 68 closed out — a net gain of 83 holders — while 333 added to existing stakes and 265 trimmed.
The largest buyer was BlackRock, adding an estimated $168M. The largest seller was Greenvale Capital, exiting entirely with an estimated $171M sold.
- 871 institutional investors held ResMed (RMD) as of Q4 2024, up from 801 in Q3 2024.
- Funds reported $20.7B of ResMed stock for Q4 2024, down 2.8% quarter-over-quarter.
- 151 funds opened new ResMed positions in Q4 2024 and 68 closed out, a net change of +83 holders.
- The largest ResMed buyer in Q4 2024 was BlackRock, an estimated $168M added.
- The largest ResMed seller in Q4 2024 was Greenvale Capital, an estimated $171M sold.
Based on aggregated 13F filings for Q4 2024.